Apogee Therapeutics (APGE) Current Assets (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Current Assets of $1.1 billion for Q1 2026, up 105.89% year-over-year from $521.5 million in Q1 2025, and up 44.84% quarter-over-quarter from $741.4 million in Q4 2025.
Apogee Therapeutics (APGE) Current Assets (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Current Assets for 5 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 105.89% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 105.89% YoY), while the FY2025 annual figure was $741.4 million, up 39.95% from the prior year.
- Current Assets rose to $1.1 billion in Q1 2026 per APGE's latest filing, from $741.4 million in the prior quarter.
- Across five years, Current Assets topped out at $1.1 billion in Q1 2026 and bottomed at $130.7 million in Q2 2023.
- Historically, Current Assets has averaged $543.6 million across 5 years, with a median of $529.7 million in 2024.
- Annual changes were most pronounced in 2024 — Current Assets surged 421.82% — and 2025, when it slumped 36.45%.
- Apogee Therapeutics' Current Assets stood at $152.1 million in 2022, then jumped by 162.02% to $398.4 million in 2023, then soared by 32.96% to $529.7 million in 2024, then soared by 39.95% to $741.4 million in 2025, then jumped by 44.84% to $1.1 billion in 2026.
- Business Quant data shows APGE's Current Assets at $1.1 billion in Q1 2026, $741.4 million in Q4 2025, and $540.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | 991.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 991.73 Mn |
| Mar 31, 2026 | 1.07 Bn |
| Dec 31, 2025 | 741.36 Mn |
| Sep 30, 2025 | 540.10 Mn |
| Jun 30, 2025 | 516.12 Mn |
| Mar 31, 2025 | 521.53 Mn |
| Dec 31, 2024 | 529.71 Mn |
| Sep 30, 2024 | 534.48 Mn |
| Jun 30, 2024 | 681.85 Mn |
| Mar 31, 2024 | 820.61 Mn |
| Dec 31, 2023 | 398.41 Mn |
| Sep 30, 2023 | 426.42 Mn |
| Jun 30, 2023 | 130.67 Mn |
| Dec 31, 2022 | 152.06 Mn |